Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study.
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study.
Haematologica. 2017 Jan 25;:
Authors: Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F
Abstract
Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved inhibitors; its unique pharmacokinetic profile and oral dosing schedule, twice daily 4 hours apart, allows for continuous exposure at concentrations required for efficient tumor cell killing. In this phase 2 study, patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia received oral abexinostat at 80 mg BID for 14 days of a 21-day cycle and continued until progressive disease or unacceptable toxicity. A total of 100 patients with B-cell malignancies and T-cell lymphomas were enrolled between Oct 2011 and Jul 2014. All patients received at least 1 dose of study drug; primary reasons for discontinuation included progressive disease (56%) and adverse events (25%). Grade ≥3 adverse events and any serious adverse events were reported in 88% and 73% of pati...
Source: Haematologica - Category: Hematology Authors: Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F Tags: Haematologica Source Type: research
More News: Anemia | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Study | T-cell Lymphoma | Thrombocytopenia | Toxicology